| Q34093895 | ''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation |
| Q43855704 | A case series of de novo inflammatory bowel disease after kidney transplantation |
| Q36091792 | A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status |
| Q77725057 | A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus |
| Q33602527 | A comprehensive review of immunosuppression used for liver transplantation |
| Q38868046 | A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. |
| Q55648706 | A high frequency of CD8+CD28- T-suppressor cells contributes to maintaining stable graft function and reducing immunosuppressant dosage after liver transplantation. |
| Q77632922 | A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan |
| Q38645736 | A new immunosuppressant: tacrolimus |
| Q42411557 | A prospective randomized trial of FK506-based immunosuppression after renal transplantation |
| Q28360654 | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report |
| Q34187619 | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report |
| Q34498286 | A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results |
| Q43553083 | A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation |
| Q44101295 | A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation |
| Q28374686 | A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus |
| Q40403948 | A risk-benefit assessment of tacrolimus in transplantation |
| Q49074251 | A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants |
| Q43828567 | A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety |
| Q53708489 | Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. |
| Q35253580 | Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction |
| Q33654502 | Advances in liver transplantation: overview and status |
| Q33542106 | Advances in lung transplantation |
| Q73932596 | Advances in the development of immunosuppressive agents in organ transplantation |
| Q47759755 | Adverse symptoms of immunosuppressants: A survey of Canadian transplant clinicians |
| Q45076994 | Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation |
| Q46444540 | An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy |
| Q40906577 | An update on new immunosuppressive drugs undergoing preclinical and clinical trials: potential applications in organ transplantation |
| Q46132760 | Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience |
| Q48238550 | Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. |
| Q37637574 | Anemia post-lung transplantation: mechanisms and approach to diagnosis |
| Q51058080 | Anorexia nervosa in a pediatric renal transplant recipient and its reversal with cyclosporine. |
| Q24194518 | Antibody induction versus corticosteroid induction for liver transplant recipients |
| Q24197859 | Antibody induction versus corticosteroid induction for liver transplant recipients |
| Q24194087 | Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients |
| Q24197745 | Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients |
| Q37630718 | Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients |
| Q79228518 | Are preformed antibodies to biliary epithelial cells of clinical importance in liver transplantation? |
| Q51519850 | Arterial hypertension in liver transplant recipients. |
| Q73740656 | Atherosclerosis of the liver allograft |
| Q36337290 | Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials |
| Q43666887 | Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight |
| Q43728770 | Beta-2 microglobulin and serum creatinine for differentiating between immunoactivation and renal failure after liver transplantation |
| Q24236673 | Bile acids for liver-transplanted patients |
| Q24246504 | Bile acids for liver-transplanted patients |
| Q44976484 | Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine |
| Q92531810 | Bloodstream Infections in Early Postsurgery Liver Transplant: An Analysis of 401 Patients Over 10 Years |
| Q72371453 | Bone marrow augmentation in solid organ transplantation--any conclusions? |
| Q40973756 | CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation. |
| Q42586885 | Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice |
| Q41483382 | Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain |
| Q46610482 | Calcineurin inhibitor-mediated bilateral hippocampal injury after bone marrow transplantation |
| Q44083937 | Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus |
| Q51092432 | Care of the pediatric solid organ transplant recipient. The primary care perspective. |
| Q74298831 | Caring for the liver transplant recipient |
| Q37040508 | Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens |
| Q44101345 | Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy. |
| Q33806753 | Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients |
| Q35985673 | Chronic kidney disease stage progression in liver transplant recipients |
| Q43620791 | Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563. |
| Q28378996 | Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients |
| Q33335306 | Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities |
| Q34332261 | Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation |
| Q43613492 | Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients |
| Q45921158 | Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study. |
| Q73779388 | Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability |
| Q77424601 | Colon carcinoma in patients undergoing liver transplantation |
| Q77292779 | Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring |
| Q34257909 | Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients |
| Q36988437 | Comparative in vitro effects of calcineurin inhibitors on functional vascular relaxations of both rat thoracic and abdominal aorta |
| Q34231590 | Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation |
| Q43620676 | Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. |
| Q64924503 | Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. |
| Q46702764 | Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. |
| Q44366721 | Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation |
| Q50281568 | Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients |
| Q44663044 | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. |
| Q44052061 | Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation |
| Q74685771 | Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis |
| Q34425813 | Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipients |
| Q44812484 | Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients |
| Q77176230 | Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation |
| Q73901967 | Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy |
| Q43037856 | Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients |
| Q73214552 | Conversion to tacrolimus in hyperlipidemic patients |
| Q83345005 | Correlation between acute rejection severity and CD8-positive T cells in living related liver transplantation |
| Q32117297 | Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. |
| Q37664371 | Critical care issues in adult liver transplantation |
| Q73194059 | Current opinions on therapeutic drug monitoring of immunosuppressive drugs |
| Q34181796 | Current treatment practice in immunosuppression |
| Q46679799 | Cyclosporin A aggravates electroshock-induced convulsions in mice with a transient middle cerebral artery occlusion |
| Q36530398 | Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. |
| Q24244114 | Cyclosporin versus tacrolimus for liver transplanted patients |
| Q33646906 | Cyclosporin-induced hypertension: incidence, pathogenesis and management |
| Q73868647 | Cyclosporine A reduction and withdrawal in liver transplantation: a risk-benefit analysis |
| Q44239787 | Cyclosporine A-increased nitric oxide production in the rat dorsal hippocampus mediates convulsions |
| Q33670571 | Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles |
| Q35962173 | Cyclosporine and tacrolimus: the mainstay of immunosuppressive therapy for solid organ transplantation |
| Q31894944 | Cyclosporine challenge test revisited: does it predict outcome after solitary pancreas transplantation? |
| Q35711226 | Cyclosporine in thoracic organ transplantation |
| Q44101283 | Cyclosporine-based quadruple induction therapy versus tacrolimus-based dual immunosuppression after liver transplantation: ten-year follow-up |
| Q82577163 | Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients |
| Q43553087 | Daclizumab induction in liver transplant recipients |
| Q35535173 | De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients |
| Q41727379 | De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact |
| Q77325629 | Development of an adult liver transplant program in a public hospital in Argentina |
| Q71028136 | Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients |
| Q37962197 | Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences |
| Q34332579 | Diabetes mellitus: a major challenge in transplantation |
| Q46433931 | Direct revascularization is superior for rat parathyroid allotransplantation with FK506. |
| Q77176241 | Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients |
| Q53638116 | Distribution of class I and II human leukocyte antigens in the larynx. |
| Q28344317 | Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years |
| Q46174297 | Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. |
| Q38417581 | Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients |
| Q43651296 | Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation |
| Q47864384 | Editorial: tacrolimus-how low can you go? |
| Q31396074 | Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency |
| Q44741576 | Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients |
| Q51569379 | Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. |
| Q73219538 | Effect of donor-specific transfusion in combination with FK 506 in rat cardiac allotransplantation |
| Q36603215 | Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients. |
| Q42553743 | Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus |
| Q38555583 | Effect of orthotopic liver transplantation on employment and health status |
| Q42028499 | Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. |
| Q43905616 | Effects of mycophenolate mofetil introduction in liver transplant patients: results from an observational, non-interventional, multicenter study (LOBSTER). |
| Q74414590 | Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation |
| Q38662186 | Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. |
| Q73279352 | Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients |
| Q54422675 | End-stage renal disease in liver transplants. |
| Q44483769 | Epstein-Barr virus DNA in serum after liver transplantation--surveillance of viral activity during treatment with different immunosuppressive agents |
| Q45403489 | Epstein-barr virus-related post-transplant lymphoproliferative disorder in a renal transplant recipient treated with tacrolimus and antithymocyte globulin |
| Q40663383 | Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy |
| Q36240947 | Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients |
| Q51769735 | Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. |
| Q44046735 | Evaluation of renal function in transplant patients on tacrolimus therapy |
| Q48863359 | Evaluation of the effects of immunosuppressants on neuronal and glial cells in vitro by multinuclear magnetic resonance spectroscopy |
| Q35711203 | Evolution of immunosuppression in liver transplantation: contribution of cyclosporine |
| Q33729003 | Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection |
| Q37355472 | Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients |
| Q90428771 | Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017 |
| Q52998120 | FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. |
| Q41697821 | FK506 and the role of immunophilins in nerve regeneration |
| Q35024911 | FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension |
| Q47939846 | FK506 for primary and rescue therapy following liver transplantation |
| Q40962151 | FK506 in solid organ transplantation |
| Q43806058 | FK506 suppressed the inflammatory change of EAM in SJL/J mice |
| Q24643383 | FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology |
| Q74617295 | FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models |
| Q35711520 | FTY720: early clinical experience. |
| Q36545066 | Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. |
| Q74082571 | Fas antigen expression of hepatocytes and its modification by immunosuppressants |
| Q40671640 | Fever in the solid organ transplant patient |
| Q43833962 | Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. |
| Q44855278 | Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation |
| Q89536592 | Generic Tacrolimus (Tacrobell®) Shows Comparable Outcomes to Brand-Name Tacrolimus in the Long-Term Period After Adult Deceased Donor Liver Transplantation |
| Q92367894 | Head and neck cancer in living donor liver transplant recipients: Single center retrospective study |
| Q34206468 | Hepatic and intestinal transplantation at the University of Pittsburgh |
| Q34498238 | Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience |
| Q43831141 | Higher intracerebral concentration of tacrolimus after intermittent than continuous administration to rats |
| Q43758759 | Histological patterns of rejection using oral microemulsified cyclosporine and tacrolimus (FK506) as monotherapy induction after orthotopic liver transplantation |
| Q44918152 | Histopathology of hepatic allograft rejection after living-related liver transplantation |
| Q24596303 | History of clinical transplantation |
| Q34426372 | Hypertension and renal dysfunction in long-term liver transplant recipients |
| Q43553052 | IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation |
| Q38040507 | Immunomodulating therapy in liver transplantation: principles and practice |
| Q43894083 | Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients |
| Q33868102 | Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-kappaB activation in rat hepatocytes |
| Q46957486 | Immunosuppressant neurotoxicity in liver transplant recipients. Clinical challenges for the consultation-liaison psychiatrist |
| Q33804467 | Immunosuppressant-induced nephropathy: pathophysiology, incidence and management |
| Q41062234 | Immunosuppression after liver transplantation. |
| Q71652511 | Immunosuppression in Liver Transplantation |
| Q73862583 | Immunosuppression in Pediatric Heart Transplantation: 2003 and Beyond |
| Q35543610 | Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations |
| Q42071789 | Immunosuppression strategies after liver transplantation: a single centre experience in 57 liver transplant recipients |
| Q74686014 | Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience |
| Q73267358 | Immunosuppression: practice and trends |
| Q35987954 | Immunosuppression: towards a logical approach in liver transplantation |
| Q24235428 | Immunosuppressive T cell antibody induction therapy for liver transplant recipients |
| Q74686279 | Immunosuppressive agents: recent developments in molecular action and clinical application |
| Q32060938 | Immunosuppressive drugs in paediatric liver transplantation |
| Q74597203 | Immunosuppressive therapy |
| Q35465299 | Impact of MELD-based allocation on end-stage renal disease after liver transplantation. |
| Q58101098 | Impact of immunosuppression and acute rejection on hepatitis B recurrence |
| Q34332598 | Impact of immunosuppressive regimes on posttransplant diabetes mellitus |
| Q34936148 | Impact of immunosuppressive therapy on recurrence of hepatitis C. |
| Q42163344 | Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients |
| Q74686002 | Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation |
| Q42541527 | Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus |
| Q43712215 | Increased tacrolimus levels during diarrhea |
| Q43604560 | Induction of choleresis by immunosuppressant FK506 through stimulation of insulin-like growth factor-I production in the liver of rats |
| Q44461502 | Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients |
| Q44256901 | Influence of hepatic ischemia-reperfusion injury on tacrolimus acute renal toxicity in pigs. |
| Q52994577 | Influence of immunosuppression on patient outcome after liver transplantation. |
| Q48326027 | Inhibition of transforming growth factor-beta production in brain pericytes contributes to cyclosporin A-induced dysfunction of the blood-brain barrier |
| Q44465431 | Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials |
| Q34210636 | Intrahepatic cholestasis following liver transplantation |
| Q40159228 | Laryngeal transplantation: research, clinical experience, and future goals |
| Q34932812 | Late acute rejection after liver transplantation: the Western Canada experience |
| Q50878999 | Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). |
| Q35109007 | Liver failure, transplantation, and critical care |
| Q74604939 | Liver transplant induction trial of daclizumab to spare calcineurin inhibition |
| Q73682985 | Liver transplantation |
| Q34170394 | Liver transplantation at the millennium. Past, present, and future |
| Q34512132 | Liver transplantation in the UK. |
| Q42142894 | Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients |
| Q36340199 | Liver transplantation(). |
| Q34171069 | Liver transplantation. The pediatric challenge |
| Q35711194 | Living related liver transplantation |
| Q62617628 | Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center |
| Q34170324 | Long-term care of the liver transplant recipient |
| Q74685975 | Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group |
| Q45057607 | Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction |
| Q74348440 | Long-term follow-up of liver transplant recipients undergoing cyclosporine withdrawal |
| Q47939678 | Long-term kidney and pancreas function with tacrolimus immunosuppression following simultaneous kidney and pancreas transplantation |
| Q41109717 | Long-term management of the liver transplant recipient |
| Q45240451 | Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study |
| Q46408086 | Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database |
| Q52922055 | Long-term results after liver transplantation. |
| Q73868965 | Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients |
| Q43538036 | Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy |
| Q73457467 | Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years |
| Q33337598 | Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation |
| Q38175341 | Low-volume deceased donor liver transplantation alongside a strong living donor liver transplantation service |
| Q38737314 | Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. |
| Q73296500 | Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts |
| Q26770033 | Management of immunosuppressant agents following liver transplantation: Less is more |
| Q34266517 | Management of recurrent hepatitis C after liver transplantation |
| Q34426415 | Management of the pediatric liver transplant patient |
| Q33906170 | Manipulating immune responses with immunosuppressive agents that target NFAT. |
| Q34186451 | Massive pleural effusion in a renal transplant recipient on tacrolimus |
| Q77369514 | Mechanism of action of the calcineurin inhibitors |
| Q34791985 | Mechanisms of clinically relevant drug interactions associated with tacrolimus |
| Q35873632 | Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber |
| Q34481437 | Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy |
| Q36501716 | Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation |
| Q34170300 | Modern immunosuppression |
| Q58236174 | More effective immunosuppression with the use of FK506 after liver transplantation |
| Q44216333 | Mycophenolate mofetil for treatment of ongoing or chronic rejections after liver transplantation |
| Q44216330 | Mycophenolate mofetil reduces calcineurin inhibitor-induced side effects after liver transplantation |
| Q36755975 | Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. |
| Q47890626 | Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients |
| Q77176120 | Neoral is superior to FK 506 in liver transplantation |
| Q73453363 | Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future |
| Q55547403 | New frontiers in immunosuppression. |
| Q98613238 | New-onset Psychosis in an Immunosuppressed Patient With Kidney Transplantation: An Educational Case Report |
| Q90175984 | No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation |
| Q41502315 | Obliterative bronchiolitis |
| Q58740384 | Optimal immunosuppressor induces stable gut microbiota after liver transplantation |
| Q74686112 | Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus |
| Q34621443 | Options for induction immunosuppression in liver transplant recipients |
| Q35543618 | Organ allocation: model for end-stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else |
| Q33654989 | Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience |
| Q49508712 | Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation |
| Q45713243 | Outcome of orthotopic liver transplantation in patients with hepatitis C. |
| Q53937962 | Outcomes of Early Conversion From Prograf to Generic Tacrolimus in Adult Living Donor Liver Transplant Recipients. |
| Q28068506 | Outcomes of liver transplantation in patients with hepatorenal syndrome |
| Q43800945 | Ovariectomy aggravates convulsions and hippocampal gamma-aminobutyric acid inhibition induced by cyclosporin A in rats |
| Q39948888 | Overcoming immunological barriers in regenerative medicine |
| Q35561269 | Overview of pediatric liver transplantation |
| Q33540224 | Pediatric transplantation. |
| Q48219646 | Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route |
| Q45286559 | Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation |
| Q43554146 | Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus |
| Q43620859 | Pharmacokinetics of tacrolimus during the early phase after heart transplantation |
| Q43794136 | Pharmacological characterization of cyclosporine A-induced kaolin intake in rats |
| Q35710811 | Pharmacology of calcineurin antagonists |
| Q33896672 | Pin1 deficiency causes endothelial dysfunction and hypertension |
| Q43966879 | Post-liver transplantation diabetes mellitus: an association with hepatitis C. |
| Q41440241 | Post-transplant diabetes mellitus. The role of immunosuppression |
| Q43021649 | Posterior Reversible Encephalopathy Syndrome (PRES) as a Complication of Immunosuppressive Therapy in Renal Transplantation in Children |
| Q40982396 | Posterior Reversible Encephalopathy Syndrome after Heart Transplantation: Diagnosis and Immunosuppressive Therapy |
| Q40837233 | Posterior reversible encephalopathy syndrome in a renal allograft recipient: A complication of immunosuppression? |
| Q33988139 | Pre- and post-transplant treatment of hepatitis C. |
| Q43284783 | Predicting risk of acute rejection in patients with kidney transplants |
| Q74110651 | Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression |
| Q34287269 | Pregnancy after liver transplantation under tacrolimus |
| Q34287276 | Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years |
| Q36220172 | Prevention of hepatitis C recurrence after liver transplantation: An update |
| Q40880337 | Prevention of transplant rejection: current treatment guidelines and future developments |
| Q61941806 | Primary Induction with Mycophenolate Mofetil and Corticosteroids in a Liver Transplant Recipient with Hepatorenal Syndrome |
| Q34304992 | Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events |
| Q41485015 | Primary care of patients with renal transplants |
| Q74685712 | Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients |
| Q43740101 | Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients |
| Q34728463 | Protein therapeutics: a summary and pharmacological classification |
| Q34023397 | Psychiatric assessment in transplantation |
| Q52006608 | Psychiatric evaluations of small intestine transplantation patients. |
| Q43620825 | Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial |
| Q43975354 | Quality of life in kidney recipients: comparison of tacrolimus and cyclosporine-microemulsion |
| Q43114828 | Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. |
| Q34289636 | Randomised trialomania? The multicentre liver transplant trials of tacrolimus |
| Q43592027 | Reasons why some children receiving tacrolimus therapy require steroids more than 5 years post liver transplantation |
| Q57245409 | Recent advances in immunosuppression |
| Q36117136 | Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database |
| Q33969819 | Recurrent hepatitis C after liver transplantation |
| Q40662972 | Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB. |
| Q90450241 | Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study |
| Q44531822 | Renal function following liver transplantation for unresectable hepatoblastoma. |
| Q28362068 | Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs |
| Q51577888 | Rescue therapy with tacrolimus in simultaneous pancreas/kidney transplantation. |
| Q44247090 | Response of refractory colitis to intravenous or oral tacrolimus (FK506). |
| Q28545113 | Retracted: Comprehensive Comparison of Three Different Immunosuppressive Regimens for Liver Transplant Patients with Hepatocellular Carcinoma: Steroid-Free Immunosuppression, Induction Immunosuppression and Standard Immunosuppression |
| Q36652060 | Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation |
| Q44211421 | Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection |
| Q47939795 | Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation |
| Q34332586 | Risk factors and incidence of posttransplant diabetes mellitus |
| Q34107643 | Risk factors for chronic anemia in pediatric orthotopic liver transplantation: analysis of data from the SPLIT registry |
| Q35706187 | Risks of allogeneic hand transplantation |
| Q39122562 | SW-163A and B, novel immunosuppressants produced by Streptomyces sp. |
| Q46572785 | Safety profile of tacrolimus in patients with rheumatoid arthritis |
| Q41376164 | Seizures after orthotopic liver transplantation |
| Q33722921 | Selected drug complications and treatment conflicts in the presence of coexistent diseases |
| Q35962133 | Selection of patients for liver transplantation in 1997 and beyond |
| Q40113778 | Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. |
| Q89869509 | Sequential Cohort Analysis After Liver Transplantation Shows de Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction |
| Q51563839 | Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. |
| Q46512897 | Severe hearing loss after liver transplantation. |
| Q37621636 | Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? |
| Q58204824 | Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus |
| Q94570291 | Spotlight on Impactful Research: Long-Term Calcineurin Inhibitor Therapy and Brain Function in Patients After Liver Transplantation |
| Q44033379 | Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study |
| Q45230206 | Standard chronic immunosuppression after kidney transplantation for systemic lupus erythematosus eliminates recurrence of disease |
| Q43553077 | Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation |
| Q44461506 | Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report. |
| Q37300420 | Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits |
| Q34332602 | Strategies for risk reduction and management of posttransplant diabetes mellitus |
| Q33885258 | Stuttering priapism in a liver transplant patient with toxic levels of fk506. |
| Q44239760 | Subchronic treatment with cyclosporin A decreases the binding properties of the GABAA receptor in ovariectomized rats |
| Q39445360 | Sublingual Tacrolimus in Liver Transplantation: A Valid Option? |
| Q50464150 | Sudden hearing loss associated with tacrolimus in a liver transplant recipient. |
| Q34027429 | Surgical approaches to dilated cardiomyopathy |
| Q84997355 | Sustained Renal Response to Mycophenolate Mofetil and CNI Taper Promotes Survival in Liver Transplant Patients with CNI-Related Renal Dysfunction |
| Q36182011 | Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant |
| Q52899439 | Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function. |
| Q45237844 | Systemic toxicity of tacrolimus given by various routes and the response to dose reduction |
| Q33744081 | Tacrolimus (FK 506). |
| Q34340969 | Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet |
| Q43875168 | Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases |
| Q41449009 | Tacrolimus (FK506) is superior to cyclosporine in liver transplantation |
| Q42010174 | Tacrolimus (FK506)-Associated Renal Pathology |
| Q74685966 | Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation |
| Q28374591 | Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient |
| Q42056355 | Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery |
| Q45068928 | Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial |
| Q74414594 | Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation |
| Q46045664 | Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations |
| Q30278052 | Tacrolimus for the prevention and treatment of rejection of solid organ transplants |
| Q44230295 | Tacrolimus in pediatric liver transplantation |
| Q34330427 | Tacrolimus in pediatric renal transplantation |
| Q28087131 | Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use |
| Q73027285 | Tacrolimus in solid organ transplantation: an update |
| Q38066267 | Tacrolimus in transplant rejection |
| Q77176878 | Tacrolimus is superior to cyclosporine in liver transplantation |
| Q42448517 | Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect |
| Q40630682 | Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine. The US Multicenter FK506 Liver Study Group |
| Q77632930 | Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan |
| Q38019054 | Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. |
| Q77725043 | Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine |
| Q43553009 | Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study |
| Q34155167 | Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial |
| Q74613821 | Tacrolimus vs Neoral in renal and renal/pancreas transplantation |
| Q43620771 | Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation |
| Q42793723 | Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it? |
| Q49607446 | Tacrolimus-induced hypertrophic cardiomyopathy in a patient with dermatomyositis |
| Q45107070 | Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats |
| Q44256953 | Tacrolimus-induced neurotoxicity in kidney transplant recipients |
| Q28258318 | Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation |
| Q74686248 | Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation |
| Q73578526 | Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation |
| Q37181790 | The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation |
| Q37639714 | The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence |
| Q38057373 | The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice |
| Q34330449 | The current status of hepatic transplantation at the University of Pittsburgh |
| Q57221649 | The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans |
| Q74615850 | The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels |
| Q43553036 | The importance of early prevention of renal dysfunction in liver transplant recipients |
| Q34359339 | The mother lode of liver transplantation, with particular reference to our new journal |
| Q43062088 | The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients |
| Q48715943 | The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation |
| Q41045767 | The procurement of vital organs: a synopsis of policy from various nations and the ethical implications of policy options |
| Q37099023 | The role of tacrolimus in renal transplantation |
| Q33781412 | The role of transforming growth factor-beta in transplant rejection |
| Q41201521 | The use of therapeutic drug monitoring to optimise immunosuppressive therapy |
| Q34428221 | Therapeutic drug monitoring for immunosuppressants |
| Q43592033 | Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients |
| Q47939869 | Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. |
| Q73625537 | Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study |
| Q35549320 | Transplant immunology |
| Q73678731 | Transplantation |
| Q74686020 | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results |
| Q36837268 | Two-year data from the European multicentre tacrolimus (FK506) liver study |
| Q37902515 | Ulcerative colitis after renal transplantation: A case report and review of literature |
| Q98222297 | Understanding, predicting and achieving liver transplant tolerance: from bench to bedside |
| Q53851412 | Unique histopathological features of graft biopsies with liver function abnormalities in living donor liver transplant patients receiving basiliximab induction therapy. |
| Q89966929 | Update on Immunosuppression in Liver Transplantation |
| Q35994591 | Update on liver transplantation using cyclosporine |
| Q33693244 | Urinary biomarkers: recommendations of the Joint European/United States Workshop for future research |
| Q34371734 | Use of an automated clinical management system improves outpatient immunosuppressive care following liver transplantation |
| Q81200277 | Ushikulides A and B, immunosuppressants produced by a strain of Streptomyces sp |
| Q54078474 | What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. |
| Q35025829 | What's in the pipeline? New immunosuppressive drugs in transplantation |
| Q56777177 | Xenotransplantation |
| Q74491678 | [1997 gastroenterology update--II] |
| Q27486937 | Hepatology. |